A5063834970- COVID-19 and healthcare impacts
- Neutropenia and Cancer Infections
- COVID-19 Clinical Research Studies
- Lymphoma Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Acute Myeloid Leukemia Research
- Multiple Myeloma Research and Treatments
- CNS Lymphoma Diagnosis and Treatment
- Pharmacological Effects and Toxicity Studies
- Peptidase Inhibition and Analysis
- SARS-CoV-2 and COVID-19 Research
- Long-Term Effects of COVID-19
- Cutaneous lymphoproliferative disorders research
- Research on Leishmaniasis Studies
- Inflammatory Biomarkers in Disease Prognosis
- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Drug-Induced Hepatotoxicity and Protection
- Ear and Head Tumors
- Chronic Myeloid Leukemia Treatments
- Protein Degradation and Inhibitors
- Salivary Gland Tumors Diagnosis and Treatment
- Ferrocene Chemistry and Applications
- COVID-19 Impact on Reproduction
City Clinical Hospital
2019-2024
Sechenov University
2024
State Scientific Center of the Russian Federation - Federal Medical Biophysical Center named after A.I. Burnazyan
2023-2024
Ministry of Health of the Russian Federation
2019-2024
Federal Medical-Biological Agency
2023
Infectious Clinical Hospital No. 1
2019
Moscow City Hospital No 29
2019
BACKGROUND. Renal failures, among them dialysis-dependent kidney disease, are common complications of multiple myeloma (ММ). Hemodialysis (HD) independence is achieved in only 20 % standard induction therapy recipients. The survival program HD patients remains unsatisfactory. Autologous hematopoietic stem cell transplantation (auto-HSCT) usually planned and performed young MM patients. However, the often excluded from high-dose chemotherapy protocols with subsequent auto-HSCT due to...
Background . At the end of 2019, a new coronavirus infection caused by SARS-CoV-2 virus was registered. In March 2020, first cases COVID-19 were detected in Moscow. Patients with chronic lymphocytic leukemia, characterized profound immune dysfunction, have risk factors for severe viral disease. Aim To identify hospital mortality and course COVID-19, as well to optimize therapeutic preventive measures. Materials methods The analysis included 238 patients (142 (59 %) men 96 (41 women) leukemia...
Patients with acute leukemia are one of the most vulnerable risk groups for infection SARS-CoV-2 and severe course coronavirus infection. During first 2 years pandemic, mortality rate patients was 11-48 %, depending on type, only reached population levels in 2022. Risk factors COVID-19 old age, concomitant cardiac pathology, metabolic syndrome, absence remission. Chemotherapy administered month before hospitalization diagnosis showed statistical significance influencing hospital group...
Background . Acute myeloid leukemia (AML) is a highly aggressive oncological disease of the blood and bone marrow, requiring extremely toxic chemotherapy massive supportive treatment to achieve stable remission. Currently, there no work provide medical care these patients with high risk coronavirus infection. This paper presents results large AML patient cohort during COVID-19 pandemic. Aim To assess clinical features infection in patients. Materials methods A retrospective study included...
In December 2019, cases of severe respiratory infection were reported in Wuhan, China. The disease was caused by a new, previously undescribed coronavirus, structurally similar to the then known SARS-CoV virus. World Health Organization has named new virus SARS-CoV-2 and it causes COVID-19. problem COVID-19 is exacerbated rapid spread development life-threatening complications, main which pneumonia. Due severity condition, from 5 10 % patients are treated intensive care units. initially...
Introduction. Kidney damage at the onset of multiple myeloma (MM) is observed in 20–40 % patients, which requires renal replacement therapy 2–4 cases. Deterioration kidney function associated with frequent complications and a decline quality life, as well carries high risk early death. Aim . To analyze treatment patients first diagnosed MM, complicated by severe dialysis-dependent failure. Materials methods 62 MM glomerular filtration rate <30 ml/min /1.73 m2 participated retrospective...
Aim . To study the course of COVID-19 (COronaVIrus Disease 2019) in elderly patients with acute myeloid leukemia (AML), to analyze risk factors for unfavorable outcome. Materials and methods The paper presents our own experience treatment (age ≥65 years) AML concomitant coronavirus infection hematology departments City Clinical Hospital No. 52 (Moscow) from March 2020 June 2022. diagnosis was considered confirmed based on a positive result polymerase chain reaction an oropharyngeal...
Background . Coronavirus disease (COVID-19), caused by SARS-CoV-2, presents new challenges to hematologists, highlighting the vulnerability of patients with hematological malignancies, in particular diffuse large B-cell lymphoma (DLBCL). Identification hospital mortality risk factors is necessary for subsequent stratification into groups, which will allow further risk-based therapy. Aim To develop a prognostic model and identify DLBCL associated COVID-19. Materials methods The interim...
Background . In March 2020, oncohematologists faced the problem of severe COVID-19 coronavirus infection in patients after a high-dose chemotherapy and autologous or allogeneic bone marrow transplantation. This required review issues related to selection for blood stem cell transplantation (HSCT), development new preventive therapeutic tactics aimed at treating infectious immunological complications this category, depending on nature status underlying disease timing treatment. Aim To assess...
Background . In March 2020, doctors faced the problem of severe COVID-19 coronavirus infection in patients with multiple myeloma. This required a review issues related to selection patients, development new preventive and therapeutic tactics aimed at treating infectious immunological complications this category, depending on nature status underlying disease timing treatment. Aim To assess severity myeloma, most common features course myeloma different therapy stages (disease onset,...
Aim. To assess clinical efficacy and safety of the intensified program R-SD-EPOCH ± HDMTX (R-split-dose-EPOCH high-dose MTX) in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
 Materials & Methods. From October 2022 to August 2023, 25 DLBCL were enrolled into trial protocol. Data 23 analyzed. The age was 46–70 years (median 63 years); there 13 women 10 men. Stage II bulky tumor lesion registered 7 patients; 16 showed advanced stages (III IV). IPI stratification...
Diffuse large B-cell lymphoma is the most common immunomorphological variant of in adults. Extranodal lesions are observed a third patients at disease onset. The organs often involved gastrointestinal tract, testicles, bones, thyroid gland, and skin. Primary involvement nasal cavity paranasal sinuses occur extremely rarely cause diagnostic therapeutic difficulties. article demonstrates rare clinical case newly diagnosed diffuse with sinonasal tract involvement. It took 6 months to verify...
Aim. To evaluate the acute myeloid leukemia (AML) treatment efficacy in adults Moscow real clinical practice according to Cancer Registry data. Materials and methods. We retrospectively collected data from on permanent residents who were primary diagnosed with AML January 2019 November 2023. The effectiveness of antitumor therapy was assessed by complete remissions rate, relapses, deaths, 3-year overall relapse-free survival. Data analysis performed as 01.12.2023. Results. According...
Background. Patients with acute lymphoblastic leukemia (ALL) have been the most vulnerable group of patients at risk severe and extremely COVID-19 throughout coronavirus pandemic. Secondary immunodeficiency due to leukemia, as well antitumor treatment, predisposes development a more infection, long-term SARS-CoV-2 persistence even after complete regression symptoms. Thus, although emergence Omicron variant, infection began occur predominantly in mild form, ALL remains an urgent problem. Aim....
Background . Acute myeloid leukemia (AML) is an aggressive malignancy of the hematopoietic system. Most patients with newly diagnosed AML are 65 years age or older. Treatment this cohort difficult due to comorbidity elderly and genetic characteristics hemoblastosis, which prevents achievement significant progress in treatment, contrast younger AML. As domestic foreign studies have shown, independent universal prognosis factor for In era targeted drugs, successful treatment becoming possible....
The presented literature review presents studies, including our own, on the peculiarities of course coronavirus infection in patients with hematological malignancies, particular acute myeloid leukemia (AML). A modern classification AML is presented. It has been shown that AML, addition SARS-CoV-2 COVID-19 significantly worsens prognosis patient’s life, which makes significant changes overall survival and mortality. Factors worsening life are advanced age, comorbidities, out remission,...
Коронавирусная инфекция (COVID-19) – это острое респираторное заболевание, вызванное вирусом SARS-CoV-2, впервые было отмечено в городе Ухань (Китай) и быстро распространилось по всему миру. В условиях пандемии COVID-19 проведение специфического противоопухолевого лечения у пациентов с агрессивными В-клеточными лимфомами стало одной из сложных задач. Проведение специфической противоопухолевой терапии гемобластозами, том числе лимфопролиферативными заболеваниями, требует безотлагательного...
Диффузная крупноклеточная В-клеточная лимфома (ДВКЛ) представляет собой крайне гетерогенное опухолевое заболевание лимфоидной природы и является наиболее распространенным иммуноморфологическим вариантом из группы агрессивных неходжкинских лимфом (НХЛ). Треть ДВКЛ характеризуется первичной экстранодальной локализацией вариабельным прогнозом в зависимости от зоны поражения. Следует отметить, что именно молекулярные характеристики играют ключевую роль различиях клинических проявлений, прогнозе...
Background: The use of monoclonal anti-CD20 antibodies in patients with B-cell non-Hodgkin lymphoma causes a deep and prolonged depletion the number B-lymphocytes peripheral blood suppression humoral immune response. In context pandemic COVID-19, influence antibody therapy on outcome coronavirus infection is urgent. Aims: To study effect lymphoproliferative diseases. Methods: included 210 diseases treated at City Clinical Hospital №52 Moscow from March 2020 to November 2021 for COVID-19....
Background: In March 2020, specialists in the field of oncohematology faced problem severity coronavirus infection patients after high-dose course chemotherapy and autologous or allogeneic bone marrow transplantation. This required a revision number issues related to selection for transplantation (BMT), development new preventive therapeutic tactics aimed at treatment infectious immunological complications this category patients, depending on nature underlying disease, status disease timing...